Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who
have stage IV or recurrent soft tissue sarcoma that has been previously treated with
chemotherapy.